Navigation Links
Targeted in Medical Technology

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

MILWAUKEE, RICHMOND, Calif., ST LOUIS, PALO ALTO, Calif., and PARIS, July 23 /PRNewswire-FirstCall/ -- Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., (Nasdaq: SGMO ), Sigma-Aldrich Corporation (Nasdaq: SIAL ), Open Monoclonal Technology...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

Phase 3 PROTEGE ENCORE Clinical Trial Initiated ROCKVILLE, Md. and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Cli...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

- Company plans initiation of clinical studies; Data to be presented at AACR - BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of c...

deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention

REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics (Nasdaq: DCGN ) today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer. The two SNPs, located on chromoso...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issu...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in ovarian cancer with A...

Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio

- New Claims Cover Anti-Viral Applications of Novel Targeted Agents Under the Company's Anti-Phospholipid Technology Platform - - Anti-Viral Potential of These New Agents Supported by Recent Studies Presented at American Association of Immunologists Annual Meeting - TUSTIN, Calif., ...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MG...

Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

INDIANAPOLIS, June 4 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today reported interim data from a Phase I study of its lead product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluate...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

- Results from Gene Identification Studies Presented at ASCO Support Further Exploration of Possible Tests to Predict Response to Targeted Therapies for Colon and Breast Cancers - REDWOOD CITY, Calif., May 31 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ), ...

Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)

SAN MARINO, Calif., May 29 /PRNewswire/ -- Epeius Biotechnologies ( http://www.epeiusbiotech.com ) announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted ge...

Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)

FRIMLEY, England, May 20 /PRNewswire-FirstCall/ -- - Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic Myeloid Leukaemia (CML)(1) - Highly Targeted Nature of Tasigna(R) Tackles the Root Cause of CML Whilst...

Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine

- Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in Lidocaine Penetration Compared to a Leading Marketed Product - MELBOURNE, Australia, April 30 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced posi...

Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma

SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a...

Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy

- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus - Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of ...

Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting

Company Also Announces Receipt of Fast Track Designation from FDA, Favorable Scientific Advice from EMEA and Phase 3 Plans for the Non-Small Cell Lung Cancer Monotherapy Indication SANTA MONICA, Calif., Feb. 26 /PRNewswire/ -- Dr. Giuseppe Giaccone, Chief of the Medical Onco...

Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics

The Next Step Involves Combining the 350+ Targeted Drugs on the Market and in Clinical Development with Each Other to Block Key Pathways to Combat Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for Targeted Drugs LAKE FOREST, Calif., Feb. 19 ...

Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definit...

ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia

- New Data Presented at American Heart Association Scientific Sessions 2007 - ORLANDO, Fla., Nov. 6 /PRNewswire/ -- ARCA Discovery, a privately held biopharmaceutical company, announced today that investigators presented new data analyses on ARCA Discovery's lea...

Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions

MADISON, Wis., Oct. 15 /PRNewswire/ -- Researchers at Baylor College of Medicine and Roche NimbleGen Inc., a fully integrated part of Roche Applied Science, today have published details of a highly efficient and cost-effective method for capturing targeted regions of the genome via NimbleChip(...

St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia

A new study shows that loss of Arf gene in presence of BCR-ABL mutation leaves ALL cells vulnerable to the growth-enhancing environment of the bone marrow, helping cells develop immunity to the anti-leukemia drug imatinib MEMPHIS, Tenn., Aug. 29 /PRNewswire-USNewswire/ -- Results of a study ...

Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies

RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX News Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. Antonella Perotti, MD, Istituto Nazionale dei Tumori ...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, L...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's adva...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its T...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP...

Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy

Michael S. Singer, M.D., Ph.D. Harvard Medical School Contributing Editor With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effe...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...nopathy, uveitis, endophthalmitis and retinoblastoma. Working much like an organ-specific transdermal skin patch, the tiny cup isolates the medication targeted to the eye from being absorbed into the blood stream. This new delivery system is a safe and non-invasive way to deliver effective doses of medication...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

... and Dunn. The practice provides advanced state-of-the-art diagnostic and therapeutic services including administration of chemotherapy, biologic and targeted therapies, Computed Tomography (CT), Intensity Modulated Radiation Therapy (IMRT), laboratory and pharmacy services, and an extensive clinical trials ...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...r in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal canc...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...ther advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery tec...anized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog wh...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...the filing in 2009 of a New Drug Application for picoplatin as a second-line treatment for small cell lung cancer, with approval and commercialization targeted for 2010," said Robert De Jager, M.D., chief medical officer of Poniard. "More than 1,100 cancer patients have received picoplatin in clinical studies...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

...pharmaceutical venture enterprise has been engaged in the development of new drugs under the theme of "Physician-Oriented New Drug Innovation" and has targeted at ophthalmologic and dermatological diseases against which effective drugs are hard to come by. The company's main product, Rescula(R) eyedrop 0.12%...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

...e binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division a...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...and Personalized Science for US Oncology Research. "We are eager to leverage the US Oncology Research network to support the study." Patients targeted for the study include adults with histologically documented metastatic breast cancer with measurable disease that is ER-negative, PR-negative, and HER...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

...l company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product...
Other Tags
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
(Date:9/21/2014)... Market Research Report on ... 2009-2019 is a professional and in-depth market ... 49562-28-9) industry. The report firstly reviews the ... its classification, application and manufacturing technology.The report ... of Fenofibrate (CAS 49562-28-9) listing their product ...
(Date:9/21/2014)... September 21, 2014 An experienced review ... its newest hosting ranking list and announced that FatCow ... VPS hosting suppliers. , There has been a ... demand has resulted in an increase in the number ... different services at very affordable prices. VPS (Virtual Private ...
(Date:9/21/2014)... Md. (PRWEB) September 21, 2014 Faculty and ... with a coed preschool in Owings Mills, Md., kicked off ... with Garmin Vivofit bands. GFS is the first independent school ... taken, calories burned and even sleep patterns— as part of ... Baltimore area running and walking specialty chain. The Vivofit bands ...
(Date:9/20/2014)... 21, 2014 Recently, iFitDress.com, a well-known wedding ... beautiful party dresses . In addition, the company has ... aim of the promotion is to benefit all of its ... its online store now. , Along with beautiful party ... items. It has recently released its new sexy short prom ...
(Date:9/20/2014)... 6 Minutes to Skinny , a ... Ballantyne that is showing men and women of all ages ... body fat using simple 6-minute exercises and easy-to-follow lifestyle tips ... investigative review. , “When it comes to losing body ... out for all people,” reports Michaels. “Metabolism plays a big ...
Breaking Medicine News(10 mins):Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2
Other Contents